

In the Claims

In Claims 1, 2, 3, 4, 5 and 14 change "therapeutically amount" to --
therapeutically effective amount--.


Remarks

Applicants request entry of the amendments to the Specification in order to comply with the objection under the Sequence Rules, as raised in the pending Office Action as well as to correct typographical errors. Applicants assert no new matter is added by these amendments.

Additionally, substitute figures are submitted for Fig. 2 and Fig. 4. There have been no changes to Figs. 1a, 1b, 3a, 3b and 5-10. In substitute Figs 2 and 4 the sequence from the Sequence Listing is substituted for the existing sequence. Sequence Listing Number 3 is substituted for original Fig. 2 and Sequence Listing Number 8 is substituted for original Fig. 4. The original figures 2 and 4 had typographical errors in the amino acid sequences although the nucleotide sequences were correct. It is obvious to one of normal skill in the art that the amino acid residue listed below the codon that encodes it, from nucleotide number 373 onward for original Fig. 2 and nucleotide number 252 onward for original Fig. 4, is incorrectly typed. It is also obvious to one of normal skill in the art that the amino acid sequence in the substitute figures is the only amino acid sequence that would correspond to the nucleotide sequence. The present error resulted when the 'CR' amino acid pair at the positions noted above was typed three times instead of the necessary two times causing the codons and the amino acids they encode to be offset by two codons through the rest of the sequence. The amino acid sequence was correct in the originally filed Sequence Listing. Therefore Sequence Listing number 3 is now incorporated into Figure 2 and Sequence Listing Number 8 is incorporated into Figure 4.

We believe this response addresses all concerns of the Examiner and places the application in proper form for examination.

Respectfully submitted,



MaryAnn Wiskerchen
Agent for Applicants
Registration No. 45,511
Phone: 317-655-9326

Eli Lilly and Company
Patent Division/MW
P.O. Box 6288
Indianapolis, Indiana 46206-6288

September 19, 2002